Evaluating the costs of Escherichia coli bloodstream infections: a population-based cohort study in a large metropolitan Canadian region.

IF 3.7 Q2 INFECTIOUS DISEASES JAC-Antimicrobial Resistance Pub Date : 2024-10-25 eCollection Date: 2024-10-01 DOI:10.1093/jacamr/dlae157
Teagan L King, Elissa Rennert-May, Ranjani Somayaji, Jenine Leal, Jason E Black, John M Conly, Daniel Gregson
{"title":"Evaluating the costs of <i>Escherichia coli</i> bloodstream infections: a population-based cohort study in a large metropolitan Canadian region.","authors":"Teagan L King, Elissa Rennert-May, Ranjani Somayaji, Jenine Leal, Jason E Black, John M Conly, Daniel Gregson","doi":"10.1093/jacamr/dlae157","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>We evaluated the costs of susceptible and resistant <i>Escherichia coli</i> bloodstream infections (BSIs) in adults. Secondary outcomes were the impact of BSI on length of stay (LOS), readmissions and death.</p><p><strong>Methods: </strong>We examined a population-based retrospective cohort of blood cultures from 2011 to 2018 in Calgary, Canada, linked to microcosting and gross costing data. Propensity score matching was completed, and costs were compared between no BSI and <i>E. coli</i> BSI over 90 days using linear regression.</p><p><strong>Results: </strong>A total of 4581 BSIs in 89 673 adults experienced <i>E. coli</i> bacteraemia during the study period. The mean cost of an <i>E. coli</i> BSI at 90 days was $39 072 (SD: $95 747) in adults. Ceftriaxone-resistant (CRO-R) <i>E. coli</i>, resistant to fluoroquinolones (FQ) and trimethoprim/sulfamethoxazole, compared with susceptible <i>E. coli</i> BSI resulted in the greatest mean cost at $53 899 and the highest odds of readmission, increased LOS, and death.</p><p><strong>Conclusions: </strong><i>E. coli</i> BSI is associated with substantial costs. Total cost differences were highest in those with CRO-R <i>E. coli</i> with resistance to FQ and trimethoprim/sulfamethoxazole. Over the study period, bacteraemia secondary to these strains alone, added over $9 million to costs for healthcare in the Calgary Zone.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"6 5","pages":"dlae157"},"PeriodicalIF":3.7000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11523496/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAC-Antimicrobial Resistance","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jacamr/dlae157","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: We evaluated the costs of susceptible and resistant Escherichia coli bloodstream infections (BSIs) in adults. Secondary outcomes were the impact of BSI on length of stay (LOS), readmissions and death.

Methods: We examined a population-based retrospective cohort of blood cultures from 2011 to 2018 in Calgary, Canada, linked to microcosting and gross costing data. Propensity score matching was completed, and costs were compared between no BSI and E. coli BSI over 90 days using linear regression.

Results: A total of 4581 BSIs in 89 673 adults experienced E. coli bacteraemia during the study period. The mean cost of an E. coli BSI at 90 days was $39 072 (SD: $95 747) in adults. Ceftriaxone-resistant (CRO-R) E. coli, resistant to fluoroquinolones (FQ) and trimethoprim/sulfamethoxazole, compared with susceptible E. coli BSI resulted in the greatest mean cost at $53 899 and the highest odds of readmission, increased LOS, and death.

Conclusions: E. coli BSI is associated with substantial costs. Total cost differences were highest in those with CRO-R E. coli with resistance to FQ and trimethoprim/sulfamethoxazole. Over the study period, bacteraemia secondary to these strains alone, added over $9 million to costs for healthcare in the Calgary Zone.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评估大肠埃希菌血流感染的成本:在加拿大一个大都市地区开展的基于人群的队列研究。
目的:我们评估了成人易感性和耐药性大肠埃希菌血流感染(BSI)的成本。次要结果是 BSI 对住院时间(LOS)、再入院和死亡的影响:我们研究了加拿大卡尔加里市 2011 年至 2018 年期间基于人群的血培养回顾性队列,并将其与微观成本核算和总成本数据联系起来。我们完成了倾向得分匹配,并使用线性回归法比较了90天内无BSI和大肠杆菌BSI的成本:结果:在研究期间,89 673 名成人共经历了 4581 例 BSI,其中包括大肠杆菌菌血症。成人大肠杆菌 BSI 在 90 天内的平均费用为 39 072 美元(标度:95 747 美元)。与易感大肠杆菌 BSI 相比,对氟喹诺酮类(FQ)和三甲双氨/磺胺甲噁唑耐药的头孢曲松耐药(CRO-R)大肠杆菌导致的平均费用最高,为 53 899 美元,再次入院、延长生命周期和死亡的几率也最高:结论:大肠杆菌 BSI 与大量费用相关。对 FQ 和三甲双胍/磺胺甲噁唑耐药的 CRO-R 大肠杆菌感染者的总费用差异最大。在研究期间,仅继发于这些菌株的菌血症就使卡尔加里区的医疗成本增加了 900 多万美元。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.30
自引率
0.00%
发文量
0
审稿时长
16 weeks
期刊最新文献
Nursing home nurses' opinion profiles on the potential evolution of their role in antimicrobial stewardship and associated factors: a national cross-sectional study in France. Clinical pharmacist-led antifungal drug utilization reviews in cancer care hospital: a prospective audit and feedback. State of the art of real-life concentration monitoring of rifampicin and its implementation contextualized in resource-limited settings: the Tanzanian case. Capturing the complexity of veterinarians' antibiotic prescribing practices in the livestock sector: a meta-ethnography across contexts: Veterinarians' antibiotic prescribing in different contexts. Development of a PCR assay for rapid and accurate detection of an emerging vanB Enterococcus faecium clone in the Capital Region of Denmark.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1